Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients
- 24 February 2013
- journal article
- clinical trial
- Published by Springer Nature in Gastric Cancer
- Vol. 17 (1) , 54-60
Abstract
There have been no reports on the incidence, characteristics, treatment outcomes, and prognosis of inoperably advanced or recurrent adenocarcinoma of the esophagogastric junction (AEGJ) in Japan. We investigated the clinicopathological characteristics, treatment outcomes, and prognosis for 816 patients with esophagogastric junctional and gastric adenocarcinoma who received first-line chemotherapy between 2004 and 2009. Of 816 patients, 82 (10 %) had AEGJ. The patients with AEGJ had significantly more lung and lymph node metastasis, but less peritoneal metastasis, than those with gastric adenocarcinoma (GAC). The objective response rate to first-line chemotherapy was 23.3 % for patients with AEGJ and 22.6 % in patients with GAC (p = 0.90). The median survival was 13.0 months in AEGJ and 11.8 months in GAC (p = 0.445). In no patient was tumor site a significant prognostic factor (p = 0.472). In patients with AEGJ, ECOG PS ≥ 2, presence of liver metastasis, and absence of lung metastasis were significantly associated with poor prognosis. No significant differences were observed in treatment outcomes between advanced AEGJ and GAC. Therefore, the same chemotherapy regimen can be given as a treatment arm in future Japanese clinical trials to both patients with inoperably advanced or recurrent AEGJ and those with GAC.Keywords
This publication has 29 references indexed in Scilit:
- Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategiesGastric Cancer, 2010
- Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classificationDiseases of the Esophagus, 2009
- The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trialsAnnals of Oncology, 2009
- Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in JapanJournal of Gastroenterology and Hepatology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Benefit of mediastinal and para‐aortic lymph‐node dissection for advanced gastric cancer with esophageal invasionJournal of Surgical Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinomaAnnals of Oncology, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient DataJournal of Clinical Oncology, 2004